Creative Capital Management Investments’s ImmunityBio IBRX Stock Holding History

Creative Capital Management Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587	Buy	+67	New	+$507	﹤0.01%	1240

Other funds holding IBRX

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MFG Wealth Management Indianapolis, Indiana $140M AUM 44.72% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Davidson Kahn Capital Management Sherman Oaks, California $233M AUM 19.14% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Creative Capital Management Investments's IBRX Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in ImmunityBio (IBRX) in Q2 2026: 67 shares worth $587. The stake represents ﹤0.01% of the portfolio and ranks #1240 among its holdings.

93 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Creative Capital Management Investments held 67 shares of ImmunityBio worth $587 as of Q2 2026.
ImmunityBio was a new Creative Capital Management Investments position in Q2 2026.
ImmunityBio made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1240 holding.
93 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.